



1632
\$

PATENT

Attorney Docket No.: A-59553-2/RFT/THR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CUTHBERTSON

Serial No. 09/632,149

Filed: August 3, 2000

For: OCULAR GENE THERAPY

Examiner: NGUYEN, Q.

Group Art Unit: 1632

CERTIFICATE OF MAILING

Thereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

RECEIVED

Dated: May 5, 2003

MAY 12 2003

Signed: Jere Valles
Jere Valles

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicant wishes to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO-1449. Copies of the references are enclosed.

Also enclosed is a new copy of reference C cited in the Supplemental IDS mailed on March 24, 2003. The copy sent with the IDS mailed on March 24, 2003 contained only the odd numbered pages. The copy we received from the International Searching Authority contained only the odd numbered pages and this mistake was not noticed until after the filing of the supplemental IDS. Please accept and consider the complete copy of reference C.

Nothing in the foregoing reference is believed to disclose the invention as claimed.

Nothing herein shall constitute an admission concerning the contents of the cited reference, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

No fees are believed due with in association with this filing. However, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 468648-01106).


Respectfully submitted,

DORSEY & WHITNEY LLP

Date May 5, 2003

Richard F. Trecartin, Reg. No. 31,801
Filed under §1.34(a)

Four Embarcadero Center, Suite 3400
San Francisco, California 94111-4187
Telephone: (415) 781-1989



Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/632,149		
		Filing Date	08/03/2000		
		First Named Inventor	CUTHBERTSON		
		Group Art Unit	1636		
		Examiner Name	Nguyen, Quang		
Sheet	1	of	1	Attorney Docket Number	A-70614/RFT/THR

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ² Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
	46	Glaser et al., "Transforming growth factor- β 2 for the treatment of full-thickness macular holes", <i>Ophthalmology</i> , 99:1162-1473 (1992)				
	47	Massague, "The transforming growth factor- β family", <i>Annu. Rev. Cell. Biol.</i> 6:597-641 (1990)				
	48	Roberts, et al., "Transforming growth factor type β : Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro", <i>Proc. Natl. Acad. Sci. USA</i> , 83:4167-4171 (1986)				
	49	Smiddy, et al., "Transforming growth factor β , a biological choriorectal glue", <i>Arch Ophthalmol.</i> , 107:577-580 (1989)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible ⁶ Applicant is to place a check mark here if English Language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1110514_1